• 1
    Nyren O, Lindberg G, Lindstrom E, et al.Economic costs of functional dyspepsia. In: PharmacoEconomics. Langhorne, PA: Ad is International Ltd., 1992: 312–24.
  • 2
    Talley NJ, Colin-Jones D, Koch KL, Koch M, Nyren O, Stanyhellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 14560.
  • 3
    Feldman M & Burton ME. Histamine2-receptor antagonist standard therapy for acid-peptic diseases. N Engl J Med 1990; 323: 174955.
  • 4
    Hardy RJ & Thompson SG. Detecting and describing heterogeneity in meta-analysis. Statistics Med 1998; 17: 84156.
  • 5
    DerSimonian R & Laird N. Meta-analysis in clinical trials. Controlled Clin Trials 1986; 7: 17788.
  • 6
    Farup PG, Wetterhus S, Osnes M, Ulshagen K. Ranitidine effectively relieves symptoms in a subset of patients with functional dyspepsia. Scand J Gastroenterol 1997; 32: 7559.
  • 7
    Farup PG, Hovde O, Breder O. Are frequent short gastro-oesophageal reflux episodes the cause of symptoms in patients with non-ulcer dyspepsia responding to treatment with ranitidine? Scand J Gastroenterol 1995; 30: 82932.
  • 8
    Farup PG, Larsen S, Ulshagen K, Osnes M. Ranitidine for non-ulcer dyspepsia: a clinical study of the symptomatic effect of ranitidine and a classification and characterization of the responders to treatment. Scand J Gastroenterol 1991; 26: 120916.
  • 9
    Gotthard R, Bodemar G, Brodin U, Jonsson KA. Treatment with cimetidine, antacid, or placebo in patients with dyspepsia of unknown origin. Scand J Gastroenterol 1988; 23: 718.
  • 10
    Hansen JM, Bytzer P, Schaffalitzky de Muckadell O. Placebo-controlled trial of cisapride and nizatidine in unselected patients with functional dyspepsia. Am J Gastroenterol 1998; 93: 36874.
    Direct Link:
  • 11
    Jebbink HJA, Smout AJPM, Van Berge-Henegouwen GP, Pathophysiology and treatment of functional dyspepsia. Scand J Gastroenterol 1993; 28(Suppl. 200): 814.
  • 12
    Johannessen T, Kristensen P, Petersen H, et al.The symptomatic effect of 1-day treatment periods with cimetidine in dyspepsia: combined results from randomized, controlled, single-subject trials. Scand J Gastroenterol 1991; 26: 97480.
  • 13
    Johannessen T, Fosstvedt D, Petersen H. Experience with a multi crossover model in dyspepsia. Scand J Gastroenterol 1988; 147(Suppl.): 337.
  • 14
    Johannessen T, Fjosne U, Kleveland T, et al.Cimetidine responders non-ulcer dyspepsia. Scand J Gastroenterol 1988; 23: 32736.
  • 15
    Johannessen T, Petersen H, Kristensen D, et al.Cimetidine on-demand in dyspepsia: experience with randomized controlled single-subject trials. Scand J Gastroenterol 1992; 27: 18995.
  • 16
    Kelbaek H, Linde J, Eriksen J, et al.Controlled clinical trial of treatment with cimetidine for non-ulcer dyspepsia. Acta Med Scand 1985; 217: 2817.
  • 17
    Kleveland PM, Larsen S, Sandvik L, et al.The effect of cimetidine in non-ulcer dyspepsia. Scand J Gastroenterol 1985; 20: 1924.
  • 18
    Lance P, Wastell C, Scheller KFRA. Controlled trial of cimetidine for the treatment of nonulcer dyspepsia. J Clin Gastroenterol 1989; 8: 4148.
  • 19
    Larsen S, Farup P, Flaten O, Osnes M. The multi-crossover model for classifying patients as responders to a given treatment. Scand J Gastroenterol 1991; 26: 76370.
  • 20
    MacKinnon M, Fracp RL, Willing MB, et al.Cimetidine in the management of symptomatic patients with duodenitis. A double-blind controlled trial. Dig Dis Sci 1982; 27: 2179.
  • 21
    Muller P, Hotz J, Franz E, Simon B. Ranitidine in the treatment of non-ulcer dyspepsia. A placebo-controlled study in the Federal Republic Germany. Arzneimittelforschung 1994; 44: 11302.
  • 22
    Nesland AA & Berstad A. Effect of cimetidine in patients with non-ulcer dyspepsia and erosive prepyloric changes. Scand J Gastroenterol 1985; 20: 62935.
  • 23
    Nyren O, Hans-Olav A, Bates S, et al.Absence of therapeutic benefit from antacids or cimetidine in non-ulcer dyspepsia. N Engl J Med 1986; 314: 33943.
  • 24
    Olubuyide IO, Ayoola EA, Okubanjo AO, Atoba MA. Non-ulcer dyspepsia in Nigerians clinical and therapeutic results. Scand J Gastroenterol 1986; 21(Suppl. 124): 8387.
  • 25
    Petersen H, Loge I, Johannessen T, et al.Therapeutic response as a diagnostic tool. Scand J Gastroenterol 1987; 128(Suppl.): 10813.
  • 26
    Petersen H, Larsen S, Sandvik L, et al.Controlled trials in Gastrodyspepsia: a methodological aspect. Scand J Gastroenterol 1985; 20(Suppl. 109): 153158.
  • 27
    Reilly TG, Singh S, Cottrell J, et al.Low-dose famitidine and ranitidine as single post-prandial doses: a three-period placebo-controlled comparative trial. Aliment Pharmacol Ther 1996; 10: 74955.
  • 28
    Saunders JHB, Oliver RJ, Higson DL. Dyspepsia incidence of non-ulcer disease in a controlled trial of ranitidine in general practice. Br Med J 1986; 292: 6658.
  • 29
    Singal DM, Kumar A, Broor SL. Cimetidine in the treatment of non-ulcer dyspepsia: results of a randomized double-blind, placebo-controlled study. Curr Med Res Opin 1989; 11: 3907.
  • 30
    Talley NJ, McNeil D, Hayden A, Piper DW. Randomized, double-blind, placebo-controlled crossover trial of cimetidine and pirenzepine in nonulcer dyspepsia. Gastroenterology 1986; 91: 14956.
  • 31
    DeLattre M, Malesky M, Prinzie A. Symptomatic treatment of non-ulcer dyspepsia with cimetidine. Curr Ther Res 1985; 37: 98091.
  • 32
    LaBrooy S, Lovell D, Misiewicz JJ. The treatment of non-ulcer dyspepsia. In: Wastell C, Lance P, eds. Cimetidine. The Westminster Hospital Symposium. London: Churchill Livingstone, 1978: 131–40.
  • 33
    Dobrilla G, Comberlato M, Steele A, Vallaperta P. Drug treatment of functional dyspepsia: a meta-analysis of randomized controlled clinical trials. J Clin Gastroenterol 1989; 11: 16977.
  • 34
    Finney JS, Kinnersley N, Hughes M. Meta-analysis of antisecretory and gastrokinetic compounds in functional dyspepsia. J Clin Gastroenterol 1998; 26: 31220.
  • 35
    Poynard T, Mory B, Levoir W, Piguou JP, Naveau S, Chaput JC. Randomized clinical trials in patients with dyspepsia. In: Non-ulcer Dyspepsia: Pathophysiological, Therapeutic Approaches. Paris: John Libbey Eurotext, 1991: 227–37.
  • 36
    Soo S, Moayyedi P, Deeks J, Delaney B, Innes M, Forman D. Pharmacological interventions for non-ulcer dyspepsia (Cochrane Review). The Cochrane Library 2001; 1.
  • 37
    Veldhuyzen van Zanten SJO, Cleary C, Talley NJ, et al.Drug treatment of functional dyspepsia: a systematic analysis of trial methodology with recommendations for design of future trials. Am J Gastroenterol 1996; 91: 66073.
  • 38
    Veldhuyzen van Zanten SJO, Talley NJ, Bytzer P, Klein KB, Whorwell PJ, Zinsmeister AR. Design of treatment trials for functional gastrointestinal disorders. Gut 1999; 45(Suppl. II): 116977.
  • 39
    Jebbink HJA, Smout AJPM, Van Berge-Henegouwen GP. Pathophysiology and treatment of functional dyspepsia. Scand J Gastroenterol 1993; 28(Suppl. 200): 814.
  • 40
    Talley NJ, Meineche-Schmidt V, Paré P, et al.Efficacy of omeprazole in functional dyspepsia: double-blind, randomized, placebo-controlled trials (the Bond and Opera studies). Aliment Pharmacol Ther 1998; 12: 105565.DOI: 10.1046/j.1365-2036.1998.00410.x